Investigating the effects of metformin and automated insulin delivery on kidney and heart health in youth with Type 1 Diabetes
MANATEE-T1D: Metformin ANd AutomaTEd insulin delivery system Effects on renal vascular resistance, insulin sensitivity, and cardiometabolic function in youth with Type 1 Diabetes
This study is looking at whether taking metformin along with an automated insulin delivery system can help improve kidney and heart health in young people aged 12-21 with Type 1 Diabetes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Children's Hospital NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11210200 on NIH RePORTER |
What this research studies
This research explores how metformin, a medication commonly used for diabetes, combined with automated insulin delivery systems, can improve kidney function and heart health in young people with Type 1 Diabetes. The study involves a randomized trial where participants aged 12-21 will receive either metformin or a placebo while using an automated insulin delivery system. Researchers will measure changes in insulin sensitivity and renal vascular resistance to understand the potential benefits of this combined approach. The goal is to find effective strategies to reduce the risk of kidney and cardiovascular diseases in youth with diabetes.
Who could benefit from this research
Good fit: Ideal candidates for this research are youth aged 12-21 years with Type 1 Diabetes who are using automated insulin delivery systems.
Not a fit: Patients who are not using automated insulin delivery systems or are outside the age range may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved kidney and heart health outcomes for young people with Type 1 Diabetes.
How similar studies have performed: Previous research has shown that metformin can improve insulin sensitivity in youth with Type 1 Diabetes, but the combination with automated insulin delivery systems is a novel approach.
Where this research is happening
Seattle, United States
- Seattle Children's Hospital — Seattle, United States (Active)
Researchers
- Principal investigator: Tommerdahl, Kalie L — Seattle Children's Hospital
- Study coordinator: Tommerdahl, Kalie L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.